लोड हो रहा है...

Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months

BACKGROUND: The BRAF K601E mutation occurs in 5% of patients with melanoma, and is the third most common type of BRAF mutation. However, treatment with BRAF and mitogen-activated extracellular signal-regulated kinase (MEK) inhibitors is only approved in patients with BRAF V600-positive melanoma, and...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Exp Hematol Oncol
मुख्य लेखकों: Marconcini, Riccardo, Galli, Luca, Antonuzzo, Andrea, Bursi, Simona, Roncella, Claudia, Fontanini, Gabriella, Sensi, Elisa, Falcone, Alfredo
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: BioMed Central 2017
विषय:
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC5361706/
https://ncbi.nlm.nih.gov/pubmed/28344857
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-017-0067-4
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!